Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors
By clicking the “Apply” button, I understand that my employment application process with Takeda will commence and that the information I provide in my application will be processed in line with Takeda’s Privacy Notice and Terms
By clicking the “Apply” button, I understand that my employment application process with Takeda will commence and that the information I provide in my application will be processed in line with Takeda’s Privacy Notice and Terms
JOB DESCRIPTION: Primary Function Provides global or regional leadership for a particular regional or global clinical program. Ensures design and execution of high quality clinical studies to ensure safety and effectiveness of the company’s products. Manages clinical project team
By clicking the “Apply” button, I understand that my employment application process with Takeda will commence and that the information I provide in my application will be processed in line with Takeda’s Privacy Notice and Terms
General Information Job Advert Title: Drug Substance Lead, Upstream Bioprocess Science, CBTL, Product Research & Development Location: Tsukuba,Ibaraki Division: Product Research & Development Employment Class: Permanent Description 【募集の背景 / Purpose & Scope】 Astellas Pharma’s Product Research & Development (PR&D)
Support Worker Department: Healthcare Assistants and Support Workers Employment Type: Permanent - Full Time Location: Aire House Compensation: £13.75 / hour Description Priory Aire House is looking to recruit a Support Worker to join the team.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors
General Information Job Advert Title: Manager/ Senior Researcher, DDS, Technology Scouting & Integration Labs. 主任研究員，DDS，技術統合研究所 Location: Tsukuba,Ibaraki or Yaizu, Shizuoka Division: Product Research & Development Employment Class: Permanent Description 【募集の背景 / Purpose & Scope】 DDS (drug delivery
General Information Job Advert Title: Senior Research Associate Location: Tsukuba,Ibaraki Division: Oncology Research Employment Class: Permanent Description 【About Astellas】 Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We
At EY, we’re all in to shape your future with confidence. We’ll help you succeed in a globally connected powerhouse of diverse teams and take your career wherever you want it to go. Join EY and
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors
General Information Job Advert Title: Senior Scientist, Innate Immunity & Cancer Cell Death Biology Location: Tsukuba,Ibaraki Division: Oncology Research Employment Class: Permanent Description 【About Astellas】 Astellas is a global life sciences company committed to turning innovative
General Information Job Advert Title: Scientist I, Innate Immunity & Cancer Cell Death Biology Location: Tsukuba,Ibaraki Division: Oncology Research Employment Class: Permanent Description 【About Astellas】 Astellas is a global life sciences company committed to turning innovative
General Information Job Advert Title: Scientist I, Cancer Driver Biology Location: Tsukuba,Ibaraki Division: Oncology Research Employment Class: Permanent Description 【About Astellas】 Astellas is a global life sciences company committed to turning innovative science into VALUE for
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors